Luye Pharma Group (HKSE:02186) Total Inventories : HK$905 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Total Inventories?

Luye Pharma Group's total inventories for the quarter that ended in Dec. 2023 was HK$905 Mil. Luye Pharma Group's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$892 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Luye Pharma Group's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$-0.74.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Luye Pharma Group's Days Inventory for the six months ended in Dec. 2023 was 152.20.

Inventory Turnover measures how fast the company turns over its inventory within a year. Luye Pharma Group's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.20.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Luye Pharma Group's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.25.

Luye Pharma Group Total Inventories Historical Data

The historical data trend for Luye Pharma Group's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Total Inventories Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

686.77

725.84

913.87

863.15

905.50

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial															913.87	919.74	863.15	878.97	905.50

Luye Pharma Group Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Luye Pharma Group (HKSE:02186) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Luye Pharma Group's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(9321.475	+	0.75 * 2163.359	+	0.5 * 905.499	-	13084.025
-	0	-	1090.836)	/	3761.67
=	-0.74

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Luye Pharma Group's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	892.2335	/	1069.889	*	365 / 2
	=	152.20

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Luye Pharma Group's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1069.889	/	892.2335
	=	1.20

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Luye Pharma Group's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	892.2335	/	3542.717
	=	0.25

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Luye Pharma Group Total Inventories Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines